drugset / Trial / NCT05382546
A Pharmacokinetic Study of Intravenous NTM-001 in Healthy Chinese Subjects
NaSingle-groupOpen-labelTreatment
Summary
This will be a single center, open-label phase 1 study in healthy Chinese subjects. A total of up to 16 subjects may be enrolled to achieve a total target of 12 evaluable subjects. A full dose for NTM-001 will be defined as a 12.5 mg IV Loading Dose + 24-hour IV infusion (3.5 mg/hour).
Timeline
- Start
- 2022-05-23
- Primary completion
- 2022-07-05
- Completion
- 2023-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketorolac Tromethamine | Small molecule | 3.5 mg | Intravenous |
Indications
No indication recorded.